Literature DB >> 19816074

The relationship between cyclooxygenase-2, CD44v6, and nm23H1 in esophageal squamous cell carcinoma.

Wen-Kang Liu1, Qing Fu, Yun-Ming Li, Xiang-Yang Jiang, Mei-Ping Zhang, Zhen-Xi Zhang.   

Abstract

BACKGROUND: Esophageal cancer is the fourth most prevalent malignancy in China. The relationship between COX-2, CD44v6, and nm23H1 in esophageal squamous cell carcinoma (ESCC) remains unclear.
MATERIAL AND METHODS: Expression of COX-2, CD44v6, and nm23H1 was examined, using the streptavidin-peroxidase method, in 82 ESCC and 30 normal esophageal mucosa (NEM) samples from the Shaanxi Province in China.
RESULTS: The positive rates of COX-2, CD44v6, and nm23H1 were 73.2% (60/82), 64.6% (53/82), and 24.4% (31/82), respectively in ESCC, but 6.7% (2/30), 3.3% (1/30), and 90% (27/30), respectively in NEMs. There was a statistically significant difference between NEMs and ESCCs (p < 0.05). Expression of COX-2 showed a positive statistical correlation with expression of CD44v6 (r = 0.4732, p < 0.0001), and an inverse correlation with nm23H1 (r = -0.3226, p = 0.0035). Expression of COX-2, CD44v6, and nm23H1 had no significant correlation with gender or age (p > 0.05), but increased expression of COX-2 and CD44v6 showed statistical correlation with invasion and lymph node metastasis, respectively (p < 0.05). Decreased expression of nm23H1 was statistically correlated with lymph node metastasis (p = 0.0007) but had no correlation with invasion (p = 0.8221).
CONCLUSIONS: This is the first report of a significant correlation between COX-2, CD44v6, and nm23H1 in ESCC. This knowledge might help us to further understand the molecular mechanisms of carcinogenesis and progression of ESCC. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816074     DOI: 10.1159/000232346

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  8 in total

Review 1.  Cancer stem cell detection and isolation.

Authors:  Meysam Moghbeli; Faezeh Moghbeli; Mohammad Mahdi Forghanifard; Mohammad Reza Abbaszadegan
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

2.  Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma.

Authors:  Jun-Xing Huang; Wei Xiao; Wei-Chang Chen; Mao-Song Lin; Zheng-Xiang Song; Ping Chen; Yun-Lei Zhang; Feng-Yue Li; Rong-Yu Qian; Eeva Salminen
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 3.  Biomarkers for predicting future metastasis of human gastrointestinal tumors.

Authors:  Lui Ng; Ronnie Tung Ping Poon; Roberta Pang
Journal:  Cell Mol Life Sci       Date:  2013-01-31       Impact factor: 9.261

4.  Comparable molecular alterations in 4-nitroquinoline 1-oxide-induced oral and esophageal cancer in mice and in human esophageal cancer, associated with poor prognosis of patients.

Authors:  Zhengduo Yang; Baoxiang Guan; Taoyan Men; Junya Fujimoto; Xiaochun Xu
Journal:  In Vivo       Date:  2013 Jul-Aug       Impact factor: 2.155

Review 5.  Cancer stem cells in human digestive tract malignancies.

Authors:  Fatemeh B Rassouli; Maryam M Matin; Morvarid Saeinasab
Journal:  Tumour Biol       Date:  2015-10-07

6.  Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44.

Authors:  Jiang-Sha Zhao; Wen-Jie Li; Di Ge; Pei-Jing Zhang; Jing-Jing Li; Chun-Lai Lu; Xiao-Dan Ji; Dong-Xian Guan; Hong Gao; Li-Yan Xu; Eng-Ming Li; Harmik Soukiasian; H Phillip Koeffler; Xiao-Fan Wang; Dong Xie
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

Review 7.  Meta-Analysis of Prognostic and Clinical Significance of CD44v6 in Esophageal Cancer.

Authors:  Bangli Hu; Wei Luo; Rui-Ting Hu; You Zhou; Shan-Yu Qin; Hai-Xing Jiang
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

8.  [Circulating lymphocyte subsets in patients with lung cancer and their prognostic value].

Authors:  Jun Luo; Zhiqiang Ling; Weimin Mao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.